Male contraception now has a real chance of moving toward a practical option since the hormone-free birth control pill named YCT-529 has completed it’s first successful human safety trial. YCT-529 is a daily pill that inhibits a vitamin A metabolite from binding to receptors in the testes to stop sperm production without affecting overall hormone levels.

The phase 1 clinical trial involved a cohort of 16 healthy male volunteers that had previously had a vasectomy such that no subject risked unintentionally impregnating a partner during the study. The results indicated that YCT-529 was well-tolerated and without serious adverse events of any kind occurred with the dosing of YCT-529- these data represent critical progress in finding contraceptive alternatives in men beyond condoms and vasectomies.

The phase 1 study only evaluated safety outcomes, however dosages are estimated at 180 mg based on preliminary data. Subjects in the phase 1 project will be follow-up assessed, along with new and previously untreated subjects in ongoing phase 2 trials that are being run by YourChoice Therapeutics – the company that YCT-529 originally patented and developed.

This development is given weight by experts like Dr. Stephanie Page, an endocrinologist working at the University of Washington School of Medicine. She said there is a dire need for more reversible options for male contraception in the realm of family planning.

Animal studies have raised hopes as they have shown fertility returns within weeks after cessation of the drug—a return fertilized after 4 to 6 weeks in mice and 10 to 15 weeks in primates—thereby suggesting reversal and safety for the pill.

Professor Gunda Georg of the University of Minnesota College of Pharmacy, where YCT-529 was developed, speaks about the wider social implications of this pill: “A safe and effective male pill will provide couples with more options for birth control and encourage the fair distribution of family planning responsibilities.”

Also Read: Parenting Mistakes: Things You Should Not Talk About Infront Of Kids

Though promising, YCT-529 is still away from being marketed for a few years, dependent upon successful trials and regulatory approvals still further. In the meantime, other male contraceptive methods are also being developed, such as the hormonal gel NES/T and ADAM, a reversible vasectomy hydrogel implant.

Plans include extended trials where men will take YCT-529 for 28 to 90 days so that safety and impact on sperm parameters might be further studied.

Such an innovative approach stands as a promising step in increasing contraceptive options and enhancing reproductive autonomy for men, which may have the potential to reshape family planning across the globe.

Share

• 
• 
• 
• 
• 
•